Uniseed began as a $20 million venture fund, founded by the Universities of Queensland and Melbourne. Since then, through investment commitment from Westscheme, Western Australia's largest non-government superannuation fund, the University of New South Wales and further investment from the founding Universities, the fund has grown to over $60 million.

Uniseed has a commitment to successfully commercialise the outcomes of Australian research and ingenuity from the University of Queensland, the University of Melbourne and the University of New South Wales.

It represents an important step in forging a link between academia and business that focuses on the commercialisation of innovative ideas and inventions for global consumption.

Uniseed has strong capabilities to package research outcomes from the academic research environment.

Uniseed’s Investment Manager Richard Marshall talks about Pepfactant’s win in the Enterprize Competition

QRxPharma Successfully Completes Pivotal Phase 3 Combination Rule Study for MoxDuo^(R) IR in Patients with Post-Surgical Pain

(ASX Release, 14 April 2010)

Hatchtech Positive DeOvo Head Lice Phase II Clinical Trial Result(Media Release, 25 March 2010)

Uniseed Approves Three New Investments
(Uniseed News, 21 December 2009)

QRxPharma Announces Completion of Strategic Alliance Deal with Liaoning Nuokang Medicines Co Ltd for the Development of Venomics Assets
(ASX Release, 20 October 2009)

MoxDuo ^TM IR Demonstrates Fewer Side Effects than Percocet ^(R) - QRxPharma
(ASX Release, 25 August 2009)

Verva Announces License of Key FGFR Intellectual Property to Isis Pharmaceuticals, Inc. for the Treatment of Obesity and Other Diseases
(Media Release, 20 August 2009)

QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study for MoxDuo (TM) IV Pain Therapy
(ASX Release, 23 July 2009)

Climate Ready Grants for Uniseed Companies
(Uniseed News, 7 July 2009)